Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Viatris Inc (VTRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: VTRS (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 17.24% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.10B USD | Price to earnings Ratio - | 1Y Target Price 12.16 |
Price to earnings Ratio - | 1Y Target Price 12.16 | ||
Volume (30-day avg) 17596713 | Beta 0.91 | 52 Weeks Range 7.59 - 13.38 | Updated Date 04/7/2025 |
52 Weeks Range 7.59 - 13.38 | Updated Date 04/7/2025 | ||
Dividends yield (FY) 6.29% | Basic EPS (TTM) -0.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -4.3% | Operating Margin (TTM) 12.83% |
Management Effectiveness
Return on Assets (TTM) 2.49% | Return on Equity (TTM) -3.24% |
Valuation
Trailing PE - | Forward PE 3.56 | Enterprise Value 22323845154 | Price to Sales(TTM) 0.62 |
Enterprise Value 22323845154 | Price to Sales(TTM) 0.62 | ||
Enterprise Value to Revenue 1.51 | Enterprise Value to EBITDA 7.92 | Shares Outstanding 1193689984 | Shares Floating 1185547792 |
Shares Outstanding 1193689984 | Shares Floating 1185547792 | ||
Percent Insiders 0.5 | Percent Institutions 85.85 |
Analyst Ratings
Rating 3.2 | Target Price 13.45 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 6 | Sell 2 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Viatris Inc
Company Overview
History and Background
Viatris Inc. was formed in November 2020 through the merger of Mylan N.V. and Upjohn, a division of Pfizer. Mylan itself had a long history as a generics manufacturer. The merger aimed to create a new kind of healthcare company with a broad portfolio of medicines.
Core Business Areas
- Developed Markets: Focuses on established markets with established brands and generics.
- Emerging Markets: Focuses on growth in emerging markets, including greater China and India.
- Biosimilars: Develops biosimilar versions of complex biologic drugs.
Leadership and Structure
The CEO of Viatris is Scott A. Smith. The company has a typical corporate structure with various functional departments, including R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Lipitor (atorvastatin): Lipitor is a branded generic for cholesterol management. Competitors include other generic statins from Teva, Sandoz, and Sun Pharma. Revenue data not available, but it is a significant contributor due to volume.
- Norvasc (amlodipine): Norvasc is a branded generic for hypertension management. Competitors include Teva, Sandoz, and Accord Healthcare. Revenue data not available, but it is a significant contributor due to volume.
- EpiPen: EpiPen, a device to administer epinephrine to treat severe allergic reactions. Viatris does not currently market EpiPen, but it was a major product when it was Mylan. Competitors include Auvi-Q and generic epinephrine auto-injectors. Former Mylan Revenue for EpiPen was a significant revenue contributor, but it is not one now
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with generic drug manufacturers facing pricing pressure and the need for continuous innovation. The biosimilars market is growing rapidly.
Positioning
Viatris is positioned as a global healthcare company focused on providing access to medicines. Its competitive advantages include its broad product portfolio, global reach, and manufacturing capabilities.
Total Addressable Market (TAM)
The global generics market is estimated at hundreds of billions of dollars. The biosimilars market is growing rapidly and could reach over $100 billion in the next decade. Viatris is positioned to address a portion of both the generics and biosimilars markets.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global manufacturing and distribution network
- Established presence in key markets
- Strong biosimilars pipeline
Weaknesses
- High debt levels
- Integration challenges from the merger
- Pricing pressure on generics
- Dependence on key products
Opportunities
- Growth in emerging markets
- Expansion of the biosimilars portfolio
- Strategic acquisitions
- Partnerships and collaborations
Threats
- Increased competition from generic drug manufacturers
- Regulatory changes
- Economic downturns
- Product liability litigation
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- RDY
Competitive Landscape
Viatris faces intense competition from other generic drug manufacturers. Its size and global reach provide an advantage, but it must innovate and manage costs effectively.
Major Acquisitions
Astellas's over-the-counter (OTC) business
- Year: 2022
- Acquisition Price (USD millions): 120
- Strategic Rationale: Expand consumer healthcare portfolio and presence in key markets.
Growth Trajectory and Initiatives
Historical Growth: Growth has been impacted by the merger, integration, and divestitures.
Future Projections: Future growth is dependent on success in biosimilars and strategic initiatives. Analyst estimates vary.
Recent Initiatives: Recent initiatives include restructuring efforts, divestitures, and focusing on core business areas.
Summary
Viatris is a global healthcare company formed through a merger with a diverse portfolio of products. Viatris faces challenges related to debt and pricing pressures on generic drugs. Growth opportunities lie in biosimilars and expansion in emerging markets. Successful integration, strategic initiatives, and cost management will be crucial for future performance. Investors should watch out for regulatory changes and competition in the generic drug markets.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
RDY
Dr. Reddy’s Laboratories Ltd ADR
RDY
Dr. Reddy’s Laboratories Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
The analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Viatris Inc
Exchange NASDAQ | Headquaters Canonsburg, PA, United States | ||
IPO Launch date 2020-11-16 | CEO & Director Mr. Scott Andrew Smith Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 32000 | Website https://www.viatris.com |
Full time employees 32000 | Website https://www.viatris.com | ||
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.